로딩 중…
지수 로딩 중…
Kura Oncology, Inc.
KURA· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$9.19+2.00%
2026-08-03
Financials
Valuation Metrics
Kura Oncology, Inc.'s Market Cap is $816M. At end of 2025 it was $915M. Ranked #2602 of 3,111 in US market (top 84%), #1092 of 1,445 on NASDAQ (top 76%), #203 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 75%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $816M | US#2,602/3,111 Sec#203/269 |
| Revenue | $72M | US#2,842/3,111 Sec#143/269 |
| Net Income | $-295M | US—/3,111 Sec—/269 |
| Total Assets | $653M | US#2,648/3,111 Sec#133/269 |
| Net Assets | $108M | US#2,876/3,111 Sec#227/269 |
| Value | ||
| P/B | 7.56x | US#2,469/3,111 Sec#184/269 |
| P/S | 11.39x | US#2,703/3,111 Sec#125/269 |
| FCF Yield | -10.35% | US—/3,111 Sec—/269 |
| Profitability | ||
| ROA | -45.14% | US#2,956/3,111 Sec#204/269 |
| Op. Margin | -443.54% | US#2,900/3,111 Sec#161/269 |
| Revenue Growth | 29.47% | US#519/3,111 Sec#71/269 |
| Financial Health | ||
| Debt Ratio | 504.87% | US#2,389/3,111 Sec#236/269 |
| Total Debt | $24M | US#2,697/3,111 Sec#175/269 |
| FCF | $-84M | US#2,560/3,111 Sec#139/269 |
| Cash | $39M | US#2,685/3,111 Sec#241/269 |
| Current Ratio | 6.15x | US#389/3,111 Sec#127/269 |
| Performance | ||
| 1Y Return | 52.66% | US#734/3,111 Sec#127/269 |
| 1M Return | -17.21% | US#2,753/3,111 Sec#223/269 |
| From 52W High | -26.42% | US#2,027/3,111 Sec#151/269 |
| 1Y MDD | -39.04% | US#1,904/3,111 Sec#140/269 |
| Trading | ||
| Volume | 1,128,993 shares | US#1,310/3,111 Sec#125/269 |
| Trading Value | $10M | US#2,274/3,111 Sec#184/269 |
| Per Share | ||
| EPS | $-3.16 | US—/3,111 Sec—/269 |
| BPS | $1.98 | US#2,515/3,111 Sec#179/269 |